Submitted:
02 March 2025
Posted:
03 March 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
3.1. Cohort Demographics
3.2. Multivariate Logistic Regression Model
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| ASA | American Society of Anesthesiologists |
| AUC | Area Under the Curve |
| CI | Confidence Interval |
| CKD | Chronic Kidney Disease |
| EHR | Electronic Health Records |
| ICD | International Classification of Diseases |
| ICU | Intensive Care Unit |
| IQR | Interquartile Range |
| MOVER | Medical Informatics Operating room Vitals and Events Repository |
| OR | Odds Ratio |
| ROC | Receiver Operating Characteristic |
| SCS | Spinal Cord Stimulator |
| SD | Standard Deviation |
| SMOTE | Synthetic Minority Oversampling Technique |
| SNS | Sacral Nerve Stimulator |
References
- Lukacz, E.S.; Santiago-Lastra, Y.; Albo, M.E.; Brubaker, L. Urinary Incontinence in Women: A Review. JAMA 2017, 318, 1592-1604. [CrossRef]
- Gajewski, J.B.; Schurch, B.; Hamid, R.; Averbeck, M.; Sakakibara, R.; Agro, E.F.; Dickinson, T.; Payne, C.K.; Drake, M.J.; Haylen, B.T. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 2018, 37, 1152-1161. [CrossRef]
- Fowler, C.J.; Griffiths, D.; de Groat, W.C. The neural control of micturition. Nat Rev Neurosci 2008, 9, 453-466. [CrossRef]
- Das, A.K.; White, M.D.; Longhurst, P.A. Sacral nerve stimulation for the management of voiding dysfunction. Rev Urol 2000, 2, 43-60.
- Brazzelli, M.; Murray, A.; Fraser, C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 2006, 175, 835-841. [CrossRef]
- Brusciano, L.; Brillantino, A.; Pellino, G.; Marinello, F.; Baeten, C.I.; Digesu, A.; Naldini, G.; Gambardella, C.; Lucido, F.S.; Sturiale, A.; et al. Sacral nerve modulation for patients with fecal incontinence: long-term outcome and effects on sexual function. Updates Surg 2023, 75, 1187-1195. [CrossRef]
- Liechti, M.D.; van der Lely, S.; Knupfer, S.C.; Abt, D.; Kiss, B.; Leitner, L.; Mordasini, L.; Tornic, J.; Wollner, J.; Mehnert, U.; et al. Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction. NEJM Evid 2022, 1, EVIDoa2200071. [CrossRef]
- Assmann, R.; Douven, P.; Kleijnen, J.; van Koeveringe, G.A.; Joosten, E.A.; Melenhorst, J.; Breukink, S.O. Stimulation Parameters for Sacral Neuromodulation on Lower Urinary Tract and Bowel Dysfunction-Related Clinical Outcome: A Systematic Review. Neuromodulation 2020, 23, 1082-1093. [CrossRef]
- Zeiton, M.; Faily, S.; Nicholson, J.; Telford, K.; Sharma, A. Sacral nerve stimulation--hidden costs (uncovered). Int J Colorectal Dis 2016, 31, 1005-1010. [CrossRef]
- Hounsome, N.; Roukas, C. Cost-effectiveness of sacral nerve stimulation and percutaneous tibial nerve stimulation for faecal incontinence. Therap Adv Gastroenterol 2018, 11, 1756284818802562. [CrossRef]
- Jairam, R.; Drossaerts, J.; Marcelissen, T.; van Koeveringe, G.; Vrijens, D.; van Kerrebroeck, P. Predictive Factors in Sacral Neuromodulation: A Systematic Review. Urol Int 2022, 106, 323-343. [CrossRef]
- Gevelinger, M.M.; Sanderson, D.J.; Jaworski, E.; Doyle, P.J. Evaluation of Sacral Nerve Stimulation Device Revision and Explantation in a Single Center, Multidisciplinary Study. Neuromodulation 2020, 23, 1201-1206. [CrossRef]
- Malde, S.; Marcelissen, T.; Vrijens, D.; Apostilidis, A.; Rahnama, I.S.; Cardozo, L.; Lovick, T. Sacral nerve stimulation for refractory OAB and idiopathic urinary retention: Can phenotyping improve the outcome for patients: ICI-RS 2019? Neurourol Urodyn 2020, 39 Suppl 3, S96-S103. [CrossRef]
- Samad, M.; Angel, M.; Rinehart, J.; Kanomata, Y.; Baldi, P.; Cannesson, M. Medical Informatics Operating Room Vitals and Events Repository (MOVER): a public-access operating room database. JAMIA Open 2023, 6, ooad084. [CrossRef]
- Fabian Pedregosa, G.V., Alexandre Gramfort, Vincent Michel, Bertrand Thirion, Olivier Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, Vincent Dubourg, Jake Vanderplas, Alexandre Passos, David Cournapeau, Matthieu Brucher, Matthieu Perrot, Édouard Duchesnay. Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research 2011, 12, 2825-2830.
- McKinney, W. Data Structures for Statistical Computing in Python. Proceedings of the 9th Python in Science Conference 2010, 51-56.
- Waskom, M.L. seaborn: statistical data visualization. The Journal of Open Source Software 2021, 6, 3021.
- Cameron, A.P.; Anger, J.T.; Madison, R.; Saigal, C.S.; Clemens, J.Q.; Urologic Diseases in America, P. Battery explantation after sacral neuromodulation in the Medicare population. Neurourol Urodyn 2013, 32, 238-241. [CrossRef]
- Myer, E.N.B.; Petrikovets, A.; Slocum, P.D.; Lee, T.G.; Carter-Brooks, C.M.; Noor, N.; Carlos, D.M.; Wu, E.; Van Eck, K.; Fashokun, T.B.; et al. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study. Am J Obstet Gynecol 2018, 219, 78 e71-78 e79. [CrossRef]



| Variable | Total | Explant | No Explant | P value |
| Number of patients | 54 | 38 | 16 | |
| Sex | ||||
| Male | 7 (13.0%) | 2 (5.3%) | 4 (25.0%) | 0.0563 |
| Female | 47 (87.0%) | 36 (94.7%) | 12 (75.0%) | 0.0563 |
| Age (years ± SD) | 63.7 ± 15.9 | 63.8 ± 16.1 | 63.3 ± 15.8 | 0.8548 |
| ASA score (IQR) | 3 (2-3) | 3 (2-3) | 2 (2-3) | 0.1608 |
| Anesthesia type | ||||
| Monitored anesthesia care | 39 (72.2%) | 27 (71.1%) | 12 (75.0%) | >0.9999 |
| General anesthesia | 15 (27.8%) | 11 (28.9%) | 4 (25.0%) | >0.9999 |
| Length of stay (days ± SD) | 0.1 ± 0.5 | 0.2 ± 0.5 | 0.0 ± 0.0 | 0.5465 |
| Indications for SNS1 | ||||
| Peripheral neuropathy | 6 (11.1%) | 5 (13.2%) | 1 (6.3%) | 0.6570 |
| Low back pain | 6 (11.1%) | 4 (10.5%) | 2 (12.5%) | >0.9999 |
| Cervical pain | 3 (5.6%) | 2 (5.3%) | 1 (6.3%) | >0.9999 |
| Urinary dysfunction | 53 (98.1%) | 37 (97.4%) | 16 (100.0%) | >0.9999 |
| Past Medical History | ||||
| Cerebrovascular disease | 1 (2.0%) | 0 (0.0%) | 1 (6.3%) | 0.2963 |
| Obstructive sleep apnea | 9 (16.7%) | 4 (10.5%) | 5 (31.3%) | 0.1056 |
| Sleep disorder | 13 (24.1%) | 8 (21.1%) | 5 (31.3%) | 0.4934 |
| Hypertension | 9 (16.7%) | 6 (15.8%) | 3 (18.8%) | >0.9999 |
| Hyperlipidemia | 8 (14.8%) | 3 (7.9%) | 5 (31.4%) | 0.0413* |
| Atrial fibrillation | 3 (5.6%) | 1 (2.6%) | 2 (12.5%) | 0.2064 |
| Diabetes mellitus | 5 (9.3%) | 3 (7.9%) | 2 (12.5%) | 0.6265 |
| Chronic kidney disease | 1 (1.9%) | 0 (0.0%) | 1 (6.3%) | 0.2963 |
| Anxiety | 9 (16.7%) | 7 (18.4%) | 2 (12.5%) | 0.7093 |
| Depression | 5 (9.3%) | 5 (13.2%) | 0 (0.0%) | 0.3064 |
| Obesity | 3 (5.6%) | 2 (5.3%) | 1 (6.3%) | >0.9999 |
| Migraine | 4 (7.4%) | 4 (10.5%) | 0 (0.0%) | 0.3064 |
| Musculoskeletal pain | 15 (27.8%) | 9 (23.7%) | 6 (37.5%) | 0.3332 |
| Arthritis | 11 (20.4%) | 8 (21.1%) | 3 (18.8%) | >0.9999 |
| Malignancy | 8 (14.8%) | 8 (21.1%) | 0 (0.0%) | 0.0883 |
| Social History | ||||
| Opioid use disorder | 1 (1.9%) | 1 (2.6%) | 0 (0.0%) | >0.9999 |
| Illicit substance use | 1 (1.9%) | 1 (2.6%) | 0 (0.0%) | >0.9999 |
| Alcohol use | 1 (1.9%) | 1 (2.6%) | 0 (0.0%) | >0.9999 |
| Tobacco products | 2 (3.7%) | 0 (0.0%) | 2 (12.5%) | 0.0839 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).